Loading...
menu
Search
AI Chat
AI Strategies
Products
Markets
News
Resources
Pricing
Home
ETF
HOWL
HOWL
-
Add to Watchlist
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
$
0.000
0.000
(
0.000%
)
At close
0.000
(
0.000%
)
Aft-market
ET
Overview
Technical
News
HOWL News
Werewolf Therapeutics Cuts Workforce by 64% to Reduce Costs
2d ago
stocktwits
Werewolf Therapeutics Board Approves Key Decision
2d ago
Yahoo Finance
GH Research (GHRS) Stock Surges 22.36% Ahead of Key Update
Jan 05 2026
NASDAQ.COM
Werewolf Reports 30% Response Rate for WTX-124 Monotherapy in Melanoma Patients
Dec 18 2025
Globenewswire
Biotech Stocks Rise After Hours: Clene Jumps Ahead of ALS Update; Werewolf, Biomea, and Dyne Also Gain
Dec 03 2025
NASDAQ.COM
Biotech Stocks MODD, LAB, HOWL, COGT, LGVN, and ABCL Surge in After-Hours Trading - Nov 26
Nov 28 2025
NASDAQ.COM
Werewolf Therapeutics Announces FDA Fast Track Designation for WTX-124 in Advanced Melanoma Treatment
Oct 08 2025
NASDAQ.COM
Biotech Stocks Rally in After-Hours Trading: Cassava, Helius, Werewolf, Aytu, and Equillium Drive Late Gains
Sep 23 2025
NASDAQ.COM
Werewolf Reports No Revenue in Fiscal Q2
Aug 14 2025
NASDAQ.COM
XOMA Royalty (XOMA) Q2 Earnings and Revenues Surpass Estimates
Aug 13 2025
NASDAQ.COM
HonorHealth Research Institute patient with advanced skin cancer in remission for more than a year following clinical trial of Werewolf Therapeutics' investigational novel conditionally activated IL-2 pro-drug WTX-124
May 20 2025
Newsfilter
Werewolf Therapeutics to Participate in Hanson Wade's 6th Annual Cytokine-Based Drug Development Summit
May 13 2025
Newsfilter
Wedbush Maintains Outperform on Werewolf Therapeutics, Lowers Price Target to $6
May 09 2025
Benzinga
Werewolf Therapeutics Presents New Preclinical Data Further Characterizing its IL-10 INDUKINE Molecule, WTX-921, for the Treatment of Inflammatory Bowel Disease (IBD) at AAI Annual Meeting
May 05 2025
Newsfilter
Analysts Are Bullish on Top Healthcare Stocks: Werewolf Therapeutics (HOWL), Exelixis (EXEL)
Mar 13 2025
Business Insider
HC Wainwright & Co. Reiterates Buy on Werewolf Therapeutics, Maintains $15 Price Target
Mar 12 2025
Benzinga
Show More News
